AC Immune Beefs Up Neurodegenerative Pipeline With AFFiRiS Alpha-Synuclein Portfolio

 
• By Alaric DeArment

Deal Snapshot: The company is looking to expand its pipeline beyond Alzheimer’s, where it hit a speedbump in September with the failure of a tau-targeting drug.

businessman and businesswoman are exchanging document or contract
AC Immune is acquiring AFFiRiS's alpha-synuclein portfolio for $63.7m in cash and stock • Source: Shutterstock

More from Deals

More from Business